Accelerated hyperfractionated radiotherapy for locally advanced cervix cancer

Area of Science:

• Radiation Oncology
• Gynecologic Oncology
• Clinical Trials

Background:

• Locally advanced cervix cancer requires effective radiotherapy strategies.
• Standard fractionation radiotherapy has limitations in achieving optimal outcomes.
• Accelerated hyperfractionated radiotherapy (AHFX) is an alternative fractionation schedule.

Purpose of the Study:

• To evaluate the toxicity and clinical outcomes of AHFX in patients with locally advanced cervical cancer.
• To assess the efficacy of AHFX in achieving local tumor control.
• To determine the rate of acute and late treatment-related complications.

Main Methods:

• A prospective phase II clinical trial was conducted.
• Patients received AHFX doses of 1.25 Gy twice daily to a total pelvic dose of 57.5 Gy.
• Booster therapy was administered via brachytherapy or external beam radiation.

Main Results:

• Sixty-one patients with advanced or recurrent cervical cancer were enrolled.
• The 5-year overall survival was 27% and relapse-free survival was 36%.
• The actuarial local control rate was 66%, but severe late complications occurred in 7 patients (27%).

Conclusions:

• AHFX achieved a favorable local control rate compared to standard fractionation.
• However, the protocol resulted in a high rate of severe late complications.
• Overall survival rates were comparable to those seen with standard radiotherapy regimens.